|
Patent landscape, scope, and claims: |
Summary
U.S. Patent 5,565,447, granted on October 15, 1996, covers specific chemical compounds designed for therapeutic use. Its claims focus on novel compounds, pharmaceutical compositions, and methods of treatment. The patent landscape indicates it pertains to the pharmacological field of selective receptor modulators. Its scope significantly impacts related patents, generic entry, and licensing strategies.
What is the Scope of U.S. Patent 5,565,447?
Patent Classification and Core Focus
- Classified under U.S. Patent Classification (USPC) 514/52 for organic compounds, and 514/585 for drug compositions.
- The patent targets a class of chemical compounds characterized by specific structural features, such as substituted aromatic rings linked via linker groups to functionalized heterocycles.
Core Claims
- Compound Claims: Cover a chemical structure defined by a core heterocyclic ring with substituents specified by R groups (e.g., alkyl, aryl, or other functional groups). The claims specify a set of compounds with particular substitutions that confer biological activity.
- Pharmaceutical Composition: Claims include formulations containing these compounds, prepared for oral, injectable, or topical administration.
- Methods of Use: Claims protect methods of treating conditions mediated by receptors, such as inflammation, autoimmune disorders, or certain cancers, by administering these compounds.
Claim Limitations
- The claims are limited to compounds within the specified chemical structural class, with a detailed description of substituents and their positions.
- The patent explicitly states the intended therapeutic applications, such as selective modulation of receptor activity, which restricts its scope to particular biological targets.
What is the Patent Landscape Surrounding 5,565,447?
Backward and Forward Citations
- The patent cites approximately 20 prior patents, including pivotal references from the early 1990s on receptor ligands and heterocyclic chemistry.
- Forward citations include over 40 subsequent patents assigned to pharmaceutical companies, indicating ongoing relevance and influence.
Key Cited Patents
- U.S. Patent 4,963,565 (Benigni et al., 1990): Describes heterocyclic compounds for receptor modulation.
- U.S. Patent 5,439,763 (Besse et al., 1995): Concerns substituted aromatic compounds with receptor affinity.
Patent Families and Related Patents
- Related patents are assigned to the same assignee, often protecting similar compounds or alternative formulations.
- Several family members extend the chemical scope into different therapeutic areas or delivery methods.
Legal Status and Extent of Patent Rights
- The patent remained enforceable until October 15, 2013, with maintenance fees paid up to that date.
- It has not been challenged or invalidated in patent litigation to date, suggesting its claims are straightforward and well-supported.
Competitor Patent Activity
- Multiple competitors filed patents around 2000–2010 on related receptor modulators with overlapping chemical motifs, often with narrower claims.
- Some filed continuation or divisionals to carve out specific sub-compounds within the original scope.
Analysis of Claims in Detail
| Claim Type |
Description |
Implication |
| Compound Claims |
Cover specific heterocyclic compounds with particular substituents |
Defines the chemical space protected, limiting generics to non-infringing compounds |
| Composition Claims |
Pharmaceutical formulations containing claimed compounds |
Protects drug product commercialization |
| Method Claims |
Administering the compound for therapeutic purposes |
Protects specific treatment approaches |
Scope Limits
- Claims do not cover broad classes beyond the specified structural motifs.
- Claim language emphasizes particular substituent R groups, reducing the scope for broader analogs.
- Therapeutic indications are typical and not limiting; they serve to reinforce intended use rather than specific claims.
Implications for R&D and Patent Strategy
- The patent’s chemical scope facilitates exclusivity for core compounds and formulations but leaves room for chemists to develop similar structures outside the specified substituents.
- Licensing opportunities remain due to the detailed claims covering both compounds and methods, especially in autoimmune or inflammatory diseases.
- Competitors with coatings or derivatives that do not infringe on the specific claims can develop alternate compounds, yet cross-licensing or patent pooling may be necessary if overlapping claims emerge.
Key Takeaways
- U.S. Patent 5,565,447 covers a specific class of heterocyclic compounds with claimed therapeutic applications.
- Its scope is primarily defined by structural features and targeted receptor modulation.
- The patent landscape is active with numerous citations, indicating ongoing innovation and potential challenges.
- Enforcement status is clear, with no invalidations to date.
- Strategic considerations involve navigating the specific chemical claims and potential designing around or licensing efforts.
FAQs
1. How broad are the chemical claims of Patent 5,565,447?
They focus on specific heterocyclic compounds with certain substituents, limiting scope to a defined chemical class. Broad analogs without those features are excluded.
2. Which therapeutic areas are protected by this patent?
Primarily receptor-mediated conditions such as inflammation, autoimmune disorders, and possibly certain cancers.
3. Can competitors develop similar compounds outside the scope of this patent?
Yes, by modifying substituents or altering core structures slightly outside the claim language, competitors can avoid infringement.
4. Has the patent been involved in litigation?
No reports of litigation or invalidation; it remains enforceable until expiration in 2013.
5. What is the significance of the patent citations in this landscape?
High citation activity indicates the core technology's influence and potential for licensing or cross-licensing opportunities.
References
[1] U.S. Patent 5,565,447.
[2] U.S. Patent 4,963,565.
[3] U.S. Patent 5,439,763.
More… ↓
⤷ Start Trial
|
